Washington Update from Congressman Paul Gosar DDS
Congressman Paul Gosar (AZ-4th District) is a health care provider and small business owner who is focused on bringing jobs back to the district, reforming health care, reining in government spending and ensuring that his constituents are involved in the solution process. Congressman Paul Gosar serves on the House Committee on Oversight and Government Reform including as the Vice Chairman of the House Subcommittee on Energy Policy, Health Care, and Entitlements which has oversight over federal health care policy, food and drug safety, energy policy, solvency of federal entitlement programs. He also serves on the Subcommittee on Economic Growth, Job Creation, and Regulatory Affairs which has oversight jurisdiction regulatory affairs, impediments to economic growth and job creation, monetary policy, banking, infrastructure, and tax policy as well as the Subcommittee on National Security which has Oversight jurisdiction over national security, homeland security, foreign operations, immigration, emergency management, and criminal justice.
Leadership Insights - Panel
Heather Morel, VP/GM McKesson Specialty Health, Dr. Jeffrey Trent, CEO and Chief Scientific Officer, TGen, Michele Y. Halyard, M.D, vice dean, Mayo Medical School – Arizona Campus, Dr. Ronald Korn, Medical Director, Virginia G. Piper cancer Center.
Paul Keim, Phd - 2012 Bioscience Researcher of the Year
Dr. Paul Keim is the Cowden Endowed Chair of Microbiology at Northern Arizona University (NAU), the Director of Pathogen Genomics at the Translational Genomics Research Institute (TGen) and research affiliate at Los Alamos National Laboratory (LANL).
Dr. Keim’s research focuses on the advancement of forensics and genomics analysis of bacterial pathogens. You may know this globally recognized researcher as ” Doctor Anthrax” (a moniker he gained after 9-11) but there is a lot more to the work Dr. Keim and his team focus on every day.
Flagship Biosciences - AZBio Company of the Year | 2012 Finalist
Flagship Biosciences provides quantitative tissue analysis services for pharmaceutical and medical device development. Flagship offers a broad range of tissue assessment options, achieved through a diverse set of approaches.Flagship Biosciences provides tissue analysis solutions to over sixty biotech, pharmaceutical, and medical device clients, with global programs in place for tissue-based companion diagnostics with three of the largest pharmaceutical companies in the world. Their sales grew 400% in 2011, and are on track to triple again in 2012. Flagship scientists published seven peer-reviewed articles in 2011, and filed 4 patent applications during the year. However, the largest development for Flagship was the acquisition of a histology and immunohistochemistry laboratory during the close 2011 which has added tissue procurement to complete their tissue-based analysis operations. Finally, the company’s image analysis technology won a best poster award at the Pathology Visions 2011 conference in San Diego, and a best presentation award at the Pathology Informatics 2011 meeting in Pittsburgh The company is currently working on a medical device spinout of their existing operations and expansion into Phoenix later this year. Committed to growing not only the company but also Arizona’s bioscience talent pool, the company currently utilizes many students from Northern Arizona University. Flagship Biosciences was honored in 2011 with the 2011 AZBio Fast Lane Award.
A Global Perspective from executives of Arizona’s Bioscience Companies on why they are in Arizona
- Bob Bosserman, CEO, Medelis
- Janet Spear, Plant Manager, Celgene
- Joan Koerber-Walker, president & CEO, AZBio (moderator)
- Dr. Ken Wertman, Scientific Director, Sanofi, Oro Valley
- Dr. Phil Miller, Ventana
INanoBio Company Presentation
Bharath Takulapalli, Founder & CEO, INanoBio
INanoBio is developing advanced nano sensor technologies for ultra-fast Genome Sequencing & Personalized Diagnostics. With our unique capability combining both nanotechnology and biomedicine, we aim to develop high-impact solutions for personalized healthcare of the future.
Clinical Trials in Arizona - Project HoneyBee
About Project Honey Bee: Recent advances in information technology and explosive growth in sophisticated but inexpensive data capture devices—biosensors—promise to revolutionize our ability to detect, diagnose, and prevent disease. By developing the ability to continuously record physiological parameters, we will pinpoint the transition from health to disease and intervene more effectively for improved health outcomes at a reduced cost. Importantly, our validation process is disease, device, and outcome-agnostic, particularly one that can handle the large variety of devices for clinical settings. We leverage our extensive experience in the careful validation of biomarkers for clinical application with a parallel methodology aimed at the utilization of physiological metrics obtained from wearable biosensors to address key clinical problems. To accomplish this goal, we enlist the considerable multidisciplinary resources of Arizona State University, while partnering with health systems such as the Mayo Clinic and Banner Healthcare in the United States and with Chang Gung University and Hospital system in Taiwan.
Advancing Innovation Thru Public Private Partnerships - Critical Path Institute
Martha Brumfield, PhD – President & CEO
The Critical Path Institute
Public Private Partnerships were envisioned by the FDA 10 years ago in their report “Stagnation and Innovation” and C-Path is one of the few organizations that has successfully implemented parts of this vision. The uniqueness of being a “neutral, third-party” enticed competitive biopharmaceutical companies to join together in sharing expertise and actual data toward the greater benefit for advancing techniques to develop medicines faster and get them to the patients who are waiting. FDA, EMA and PMDA have collaborated in each of C-Path’s 7 global consortia in offering advice toward a formal regulatory acceptance of new tools and methods. The presentation will review successes from two of these consortia which are focused on developing biomarkers and modeling and simulation tools to expedite new treatments for Alzheimer’s disease and Polycystic Kidney disease.